Literature DB >> 33400841

A comparison of surgical resection and liver transplantation in the treatment of intrahepatic cholangiocarcinoma in the era of modern chemotherapy: An analysis of the National Cancer Database.

Jonathan J Hue1, Flavio G Rocha2, John B Ammori1, Jeffrey M Hardacre1, Luke D Rothermel1, Kenneth D Chavin3, Jordan M Winter1, Lee M Ocuin4.   

Abstract

BACKGROUND: The main surgical approach to patients with localized intrahepatic cholangiocarcinoma (ICC) is hepatectomy, but transplantation has been described. A comparison of outcomes between these surgical approaches is necessary to determine if one is preferable.
METHODS: Patients with ICC were identified using the National Cancer Database (2010-2016). Patients were grouped based on operation and matched 1:1 by propensity score. Pathologic and postoperative outcomes, as well as overall survival were analyzed.
RESULTS: There were 1879 hepatectomy and 74 liver transplantation patients. Before matching, transplantation patients were younger and more often treated at academic centers. More patients who underwent a transplantation received neoadjuvant chemotherapy (70.3% vs. 12.8%). Patients who underwent transplantation had more pathologic T0 (7.7% vs. 0.4%) and T1 (47.7% vs. 42.1%) tumors (p < .001). There were no differences in length of stay, unplanned readmissions, 30/90-day mortality, or median survival between groups (36.1 vs. 36.1 months, p = .34). After matching (n = 57/group), there were no differences in postoperative outcomes or survival between transplantation or hepatectomy (36.1 vs. 33.6 months, p = .57).
CONCLUSION: Among patients with ICC, hepatectomy and liver transplantation were associated with similar postoperative outcomes and survival. In light of the resources and chronic immunosuppression required for transplantation, hepatectomy seems preferable for localized ICC.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  cholangiocarcinoma; hepatectomy; liver transplantation; survival analysis

Year:  2021        PMID: 33400841     DOI: 10.1002/jso.26370

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

1.  Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States.

Authors:  Yi-Te Lee; Amit G Singal; Marie Lauzon; Vatche G Agopian; Michael Luu; Mazen Noureddin; Tsuyoshi Todo; Irene K Kim; Marc L Friedman; Kambiz Kosari; Nicholas N Nissen; Lewis R Roberts; Julie K Heimbach; Gregory J Gores; Ju Dong Yang
Journal:  Cancer       Date:  2022-08-23       Impact factor: 6.921

2.  CircSETD3 (hsa_circ_0000567) inhibits proliferation and induces apoptosis in cholangiocarcinoma cells via downregulation of microRNA-421 expression.

Authors:  Wei Xiong; Aiqing Zhang; Xiuli Xiao; Wenjuan Liu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 3.  Liver transplantation for intrahepatic and hilar cholangiocellular carcinoma: Most recent updates in the literature.

Authors:  Susumu Eguchi; Masaaki Hidaka; Takanobu Hara; Hajime Matsushima; Akihiko Soyama
Journal:  Ann Gastroenterol Surg       Date:  2022-03-23

Review 4.  The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma.

Authors:  Guergana Panayotova; Jarot Guerra; James V Guarrera; Keri E Lunsford
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.